IONS
Ionis Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +1.5% ·
net new positions -6.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | -1 | 48.54K | $2.16M | n/a | −2 |
| Q2 2026 | 137 | +2 | 148.57M | $11.08B | +6 | −5 |
| Q1 2026 | 139 | -2 | 142.62M | $9.86B | +6 | −9 |
| Q4 2025 | 142 | 0 | 143.10M | $10.36B | +1 | n/a |
| Q3 2025 | 25 | +4 | 95.56M | $6.25B | +5 | −2 |
| Q2 2025 | 19 | +1 | 95.25M | $3.76B | +1 | n/a |
| Q1 2025 | 15 | -1 | 43.90M | $1.32B | +1 | −2 |
| Q4 2024 | 16 | -1 | 43.25M | $1.51B | n/a | −1 |
| Q3 2024 | 16 | -1 | 34.86M | $1.40B | n/a | −1 |
| Q2 2024 | 17 | n/a | 24.68M | $1.18B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 12.36M | +7.8% | $372.96M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.42M | -3.0% | $253.92M | 0.0% | ▼ Trim | 4 | SEC ↗ ×9 |
| 3 | State Street Global Advisors ✦ (passive) | 4.85M | -10.7% | $146.18M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 4 | Citadel Advisors ✦ | 3.48M | +60.7% | $104.99M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | T. Rowe Price ✦ | 3.27M | -14.7% | $98.51M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 6 | Tweedy, Browne ✦ | 2.98M | -8.2% | $90.01M | 8.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.84M | +5.8% | $85.80M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 1.69M | +83.0% | $50.86M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 1.08M | +291.1% | $32.45M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | ARK Investment Management ✦ | 1.00M | -2.4% | $30.19M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 858.23K | -50.0% | $25.89M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | Millennium Management ✦ | 635.37K | -17.9% | $19.17M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 287.20K | New | $8.66M | 0.0% | New | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 153.51K | -25.3% | $4.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Marshall Wace ✦ | 9.10K | -98.9% | $274,608 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $8.66M | 0.0% |
Exited
| D. E. Shaw & Co. | $808,380 | was 0.0% |
| Gotham Asset Management | $218,850 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 490 holders, 170.17M shares, $11.94B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.36K sh · $59,082
Officer · 53 sh · $2,308
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology